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Abstract
Background: RNA-Seq has become a key technology in transcriptome studies because it can quantify overall
expression levels and the degree of alternative splicing for each gene simultaneously. To interpret high-throughout
transcriptome profiling data, functional enrichment analysis is critical. However, existing functional analysis methods
can only account for differential expression, leaving differential splicing out altogether.
Results: In this work, we present a novel approach to derive biological insight by integrating differential expression
and splicing from RNA-Seq data with functional gene set analysis. This approach designated SeqGSEA, uses count
data modelling with negative binomial distributions to first score differential expression and splicing in each gene,
respectively, followed by two strategies to combine the two scores for integrated gene set enrichment analysis.
Method comparison results and biological insight analysis on an artificial data set and three real RNA-Seq data sets
indicate that our approach outperforms alternative analysis pipelines and can detect biological meaningful gene
sets with high confidence, and that it has the ability to determine if transcription or splicing is their predominant
regulatory mechanism.
Conclusions: By integrating differential expression and splicing, the proposed method SeqGSEA is particularly
useful for efficiently translating RNA-Seq data to biological discoveries.
Background
Transcriptome sequencing (RNA-Seq) is an increasingly
important technology for transcriptome studies using the
high-throughput sequencing (HTS) platforms. RNA-Seq
reads can be used to measure overall expression levels by
counting reads from each gene including different spliced
isoforms collectively. More importantly the higher resolu-
tion can be used to detect transcript variants due to alter-
native splicing (AS), as well as alternative transcription
start sites and alternative polyadenylation sites [1-4].
A number of recent studies have utilized RNA-Seq to
quantify disease-associated transcriptome changes or dis-
criminate between subtypes and help illuminate the mole-
cular pathology of complex diseases at the RNA level
(e.g., [5-8]).
In case-control transcriptome studies, identifying dif-
ferentially expressed genes (DEGs) in a genome-wide
scale is regarded as the first priority task since microar-
rays were applied to profile gene expressions. Existing
DEG analysis tools dealing with RNA-Seq (such as DEG-
seq [9] and Cufflinks [10]) usually generate large lists of
“interesting” genes or genome-scale gene ranks that can
be used to generate new biological insight. The biological
interpretation of DEGs has been assisted by computa-
tional functional analysis based on accumulated biologi-
cal knowledge. This has culminated in databases such as
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
[11] which aid in assembling the most enriched func-
tional categories like pathways. According to the input
type, functional enrichment tools can be categorized into
two classes. The more traditional class is to take a list of
preselected “interesting” genes, and applies statistical
methods dealing with contingency tables to test the
enrichment of each annotated gene set. The other class is
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reviewed as a cutoff-free strategy, which ranks all expressed
genes according to the strength of expression difference,
and adopts Kolmogorov-Smirnov-like tests to obtain
enrichment significance. The cutoff-free strategy, which
avoids choosing arbitrary cutoffs and can accumulate subtle
expression changes of genes in the same set, has attracted a
great deal of attention. Among them, Gene Set Enrichment
Analysis (GSEA) [12] is a highly effective method, and has
been successfully used in studying functional enrichment
between two biological groups (e.g., [13]).
Originated for analysing microarray data, GSEA and
its variants/extensions [12,14,15] take overall RNA
abundance levels as a starting point, without regarding
the differences between individual transcripts resulted
from alternative splicing in genes. Evidence has shown
that gene transcription and splicing take place simulta-
neously [16], and alternative splicing which occurs
extensively [17] can substantially expand the variability
of mRNAs from a limited number of genes in higher
eukaryotes (e.g., in human [18]), leading to a poly-
morphism of protein structures and functions [19].
With RNA-Seq replacing microarrays, the ability to
detect and quantify expression differences in individual
transcripts after splicing, or equivalently the degree of
alternative splicing in genes, is maturing. As an impor-
tant regulatory mechanism in eukaryotes, alternative
splicing should, and currently is able to, be taken into
account in differential expression analysis. To the best
of our knowledge, however, no tools till now have been
able to integrate alternative splicing with each gene’s
overall expression for functional analysis.
Here we present a novel approach, named SeqGSEA,
which first quantifies expression differences for each gene
from exon read counts in two respects - overall expression
and alternative splicing, and then combines the two
respects for one integrated GSEA run. We modelled the
read counts with negative binomial distributions, suitable
for count data and capable of accounting for biological
variation, and applied two strategies to integrate differen-
tial expression and splicing. Results on an artificial data set
and real RNA-Seq data sets indicated that our approach
can identify biologically meaningful gene sets through uti-
lizing both overall expression and alternative splicing.
Method comparison studies showed that the new
approach outperformed other alternative pipelines for
functional analysis of RNA-Seq data.
Methods
Basic assumptions
Gene expression at the RNA level can be recognized as
either the total expression abundance of a gene regardless
of the expression heterogeneity in individual isoforms or
as individually expression proportion of discrete isoforms
of a gene resulting from AS including the usage of
alternative transcription start sites and alternative ploy
(A) sites [20]. When comparing two groups of samples,
we term the analysis regarding differential overall express
of a gene, followed by microarray studies, as differential
expression (DE), whilst the analysis regarding isoform
proportion changes as differential splicing (DS). SeqG-
SEA integrates DE and DS of each gene from RNA-seq
data to conduct gene set enrichment analysis.
Currently there are two main strategies for accounting
AS from RNA-seq data: exon-centroid and isoform-
centroid [21]. In short, the exon-centroid methods are
based on exon expression levels, transforming the pro-
blem to detecting differential exon usage. In contrast, the
isoform-centroid methods infer individual splice-isoform
expression proportions in each gene first, and then quan-
tify changes of the isoform expression between samples.
To avoid introducing extra noises or biases in isoform
expression level inference, SeqGSEA presented here
quantifies AS between biological groups in an exon-
centroid fashion.
Exon-centroid methods require read counts on each
exon, of which the sum in a gene is exactly the input for
computing overall expression changes. Known that there
are at least seven types of AS [20] including alternative
3’/5’ splice sites, therefore read counts based on the bio-
logical exon definition will, however, not sensitive to
those types. In this approach, we define sub-exons as
non-overlapping continuous exon fragments due to any
possible splice sites (Supplementary Figure S1 in Supple-
mentary Materials; all Supplementary Materials are in
Additional file 1). Let X(g)ij denote read counts on sub-
exon i (i = 1,2,..., N(g)) in gene g (g = 1,2,...,G) of sample j
(j = 1,2,..., M ). By summing up the read counts of all
sub-exons in a gene, the read count of gene g can be






ij . Thus, dif-
ferential gene expression analysis is divided into two sub-
questions: DE analysis using gene read counts Y(g)j , and
DS analysis based on sub-exon read counts X(g)ij in gene g
given the total count Y(g)j .
Over-dispersion is frequently observed in modeling read
counts from RNA-Seq due to the non-uniform read distri-
bution [22]. To solve this problem and account for biolo-
gical variability when comparing groups of biological
subjects, negative binomial (NB) distributions have been
proposed to model the count data [23-26]. The NB distri-
bution can be written in various forms with parameters,
but those can be uniquely determined by its mean μ and
variance s2, as NB(μ, s2). The mean parameter μ is the
expectation value of the observed counts, while the var-
iance parameter s2 includes a dispersion term, written as
s2 = μ + μ2, where  is the dispersion parameter.
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DE and DS scores
Based on our modeling assumptions, we further borrow
the idea from Anders and Huber’s work [25] and our
previous work [27] to derive DE and DS scores, repre-
senting the degree of differential overall expression and
alternative splicing in each gene, respectively. Basically,
a DE or DS score is a statistic in the form of squared
difference of parameter estimates, divided by the sum of
parameter variances. Note that by definition the DE or
DS scores are all of non-negative values, and therefore
so are gene scores (defined in the following sub-section),
which makes it unable to tell a gene is exactly up or
down regulated in the studied group. Two major rea-
sons are considered to ignore the direction of expression
changes. First, DS itself is of no directions; it will be
meaningless to integrate one directed score with an
undirected one. Second, it is also reasonable to consider
only the absolute overall expression changes regardless
of the direction. In biological pathways, reciprocal genes,
such as those involved in feedback loops, are usually
inversely regulated [15,28]. Taking both the up- and
down-regulated components together would therefore
reduce false-negatives that can occur in methodologies
that consider the regulation direction.
Using NB distributions to model Y(g)j , we can write
Y(g)j ∼ NB(μgj, σ 2gj), where μgj = sjqg,r(j). That is, the mean
parameter μgj is the product of a size factor sj indicating
the sequencing depth for sample j, and qg,r(j), which is pro-
portional to the expectation value for gene g in group r(j).
To measure the overall expression changes between group





where qˆg,A is the estimate of the expected expression qg,A
of group A, and Vˆ(qg,A) denotes the variance estimate of
qg,A; those with subscript B are for group B. The detailed
derivation of parameter estimation can be found in Sup-
plementary Note #1 in Supplementary Materials. Note
that in the procedure, we use only the samples from one
group (without information sharing across groups) to esti-
mate the dispersion parameters. This is because SeqGSEA
requires a moderate number of replicates in each group
for the purpose of permutation, so that the per-group data
could be enough to get stable estimates.
Similarly, we can define DS scores from sub-exon read
counts as an average value across all sub-exons in a gene,
















where pˆ(g)i,A is the estimate of the expected read count





variance estimate of pˆ(g)i,A, and N
(g) is the number of sub-
exons in gene g. Please find detailed derivation of para-
meter estimations in Supplementary Note #2 in Supple-
mentary Materials.
Integrated gene scores
Based on the definition and calculation of DE and DS
scores for each gene to quantify differential overall
expression and alternative splicing, respectively, we
intend to propose an integrated gene score S(g) to depict
a gene’s RNA abundance difference with regards to the
both respects. As the two scores for one gene may not be
fully comparable, we include a normalization step before
computing the gene score. While the main GSEA algo-
rithm preforms a sample-shuffling strategy to obtain sta-
tistical significance, we need also compute DE and DS
scores on the permuted data sets. Therefore, the distribu-
tion of permutation DE (DS) scores offers an empirical
background for S(g)DE(S
(g)
DS). We take the values divided by










DS) is the mean DE (DS) score for gene g
over all permutations. An exemplified plot for normal-
ized DE (DS) scores is shown in Supplementary Figure
S2a(b) in Supplementary Materials.
Two strategies were applied to integrate DE and DS
scores into one per-gene scores, one of which is to take
weighted sums and the other is a rank-based strategy.
Linear combination is the simplest yet typically used
way for weighted summation, which writes
Sg = αS
(g)
DE,norm + (1 − α)S(g)DS,norm (4)
where a Î [0,1] is the weight balancing the contribu-
tion from DE and DS; the larger a is, the more contri-
bution from DE is applied. Two extreme cases (a = 0 or
1) make the integration degenerate to DE- or DS-only
analysis. See Supplementary Figure S2c for an exempli-
fied plot of the integrated scores. We also considered
weighted quadratic combination of the two scores, but
it behaved similar to the linear combination and as such
we ignore the discussion of the difference between lin-
ear, quadratic and high-order combination in this study.
Although the strategy to take the weighted sums of the
two scores intuitively makes sense, it does not take
account of the fact that different genes with overall expres-
sion changes and splicing changes can work together to
function in the same gene set. For example, gene a is
involved substantial DE regulation without DS but gene b
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in the same functional gene set undergoes DS but rarely
DE; the linear combination may average out the changes
and cause this gene set with expression significantly regu-
lated undetectable. To accounts for the inconsistent DE
and DS regulation of genes in the same gene set, we take a
rank-based strategy to integrate scores, which will automa-
tically assign more weights to higher ranked DE or DS
scores. First, we rank DE and DS scores in ascending









DE,norm + (1− α)γ (g)DS S(g)DS,norm)/(αγ (g)DE + (1− α)γ (g)DS ) (5)
We keep a in the formula for a global tuning of DE
and DS contribution, in addition to the data-adapted
weights given by the ranks.
Overall, regardless of a, a higher gene score indicates
that total transcript abundance, transcript composition, or
combination of both, is altered more dramatically. In prac-
tice, one may need to examine many weights for tweaking
the contribution from DE or DS, as no prior knowledge
currently gives the true contributions of DE and DS in a
particular gene set. However, as we discuss in the Results
section, with a sufficient number of weights been specified
in the analysis, the detected gene sets will be saturated.
We get gene scores on the permuted data sets in the
same way for the weighted linear combination, but for
the rank-based strategy in two different ways: using the
same ranks got from the real DE/DS scores (in a global
manner), or using permutation-specific ranks obtained
from each permutation.
Gene set enrichment analysis
Based on the integrative gene score defined above and
the prototype of GSEA originated by Mootha et al. in
2003 [13], we can convert the input RNA-Seq count data
into biological interpretations. The major merit of GSEA
is that it does not rely on any arbitrarily predefined
threshold to select “interesting” genes for functional ana-
lysis. This is very important in human disease research as
the subjects of these studies are usually subject to much
larger biological variation than more controlled condi-
tions in cell lines or model organisms [29]. Due to the
high level of heterogeneity of human samples, statistically
significant DE or DS genes are not always detected.
These problems are exemplified in high-throughput ana-
lysis of neuropathology of neuropsychiatric disorders like
schizophrenia (see comparison with Cuffdiff in Results).
Furthermore, p-values from various DE gene detection
methods may not be comparable [30], which may cause
the functional analysis results with those methods cannot
be streamlined, consequently making prediction about
the biological significance unreliable. The strategy of
GSEA successfully avoids the effect of arbitrary cutoffs
and can aggregate a composite of weak evidence to iden-
tify functional significance.
Rather than other functional analysis methods, the
GSEA algorithm takes into account how each gene is
associated with a phonotype of interest, i.e., in this study
the gene scores representing the magnitude of overall
expression and splicing alterations in the studied group.
As a result, if a gene set containing a number of genes
that have collectively high enough gene scores, the gene
set will be identified. Given an a priori defined gene set,
the algorithm will report a Kolmogorov-Smirnov-like sta-
tistic, called enrichment score (ES, Supplementary Figure
S2d), with the corresponding significance level based on
permutation tests (empirical p-values and FDRs control-
ling global false positives). We permute each sample’s
class labels 1,000 times to yield statistical significance
throughout this study. Please see Supplementary Note #3
in the Supplementary Materials for more details with for-
mulas rewritten using unified denotations in this study.
Results and discussion
Data used
Data sets. Three recently generated real RNA-Seq data
sets and one artificial data set were used for evaluating the
proposed method. The three real data sets include one
cancer transcriptome study [31] (hereafter the cancer
data), and two schizophrenia transcriptome studies in dif-
ferent human brain areas, dorsolateral prefrontal cortex
(DLPFC or BA46) [7] and superior temporal gyrus (STG
or BA22) [8]. The cancer data, downloaded from NCBI
SRA[32] with accession number SRP002628, were gener-
ated with 20 prostate cancer samples and 10 matched
benign samples by Illumina GAII, 22.2 million reads on
average for each sample. The BA46 data contains 20 schi-
zophrenia samples and 20 matched controls, and were
yielded by SOLiDv4 with an average sequencing depth 135
million reads per sample. The BA46 data used in this
study were mapped reads (against hg19) in BAM format
obtained from the authors. The BA22 data [33] were gen-
erated by Illumina GAII platform, but for a smaller sample
size (9 cases vs. 9 controls), with 28.2 million reads on
average per sample. The cancer and BA22 FASTQ data
were mapped to the human reference genome (hg19) by
Tophat (v1.4.1). Sub-exon read counts were obtained
using Python scripts based on HTSeq [34]. The artificial
data set, with various layers of differences but for charac-
terizing the proposed method, was comprised by 10 con-
trol samples from the cancer data and 9 normal samples
from the BA22 data. See Table 1 for other related experi-
ment statistics.
Gene sets. Six categories of gene sets from MSigDB v3.1
[12,35] were used in this study, including positional gene
sets (c1, n = 326), curated gene sets (c2, n = 3272; due to
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the large size of the new version and many overlapping
gene sets from different resources, v3.0 used instead),
motif gene sets (c3, n = 836), computational gene sets (c4,
n = 858), GO gene sets (c5, n = 1454), and oncogenic sig-
natures (c6, n = 189). Of those, two categories, c2 and c5,
are mainly focused in this study to report SeqGSEA’s
performance.
Correlation between DE and DS scores
To investigate the possibility of a global association
between differential overall expression and differential
splicing in the four data sets, we first investigated the cor-
relation of DE and DS scores. The artificial data set was
comprised of two RNA-Seq experiments with different tis-
sue types and demographics, so non-housekeeping genes
may be regulated by both transcription and splicing. Not
surprisingly, we observed a Pearson’s correlation coeffi-
cient of 0.23 on the artificial data set, which is significantly
larger than 0 (p-value = 0, Table 1, Supplementary Figure
S3). On the three real data sets, even if the correlation
coefficient was significantly not equal to 0, the correlation
coefficient was very close to 0, indicating the global asso-
ciations between DE and DS in these disease-related
experiments were very weak (if any), but varied in different
diseases (Table 1, Supplementary Figures S4-S6). The
weak to null association of DE and DS in disease-related
transcriptomes is consisted with previous studies using
exon arrays [36]. Nevertheless, we still observed a propor-
tion of genes having both relatively high DE scores and
high DS scores (Supplementary Figures S4-S6), suggesting
they were subject to both DE and DS regulation simulta-
neously. This observation validates the main assumption
of our approach, and therefore it is reasonable that the
integration of DE and DS with linear combination for
functional analysis would work.
Besides, we also observed that the correlation coeffi-
cient decreases with the increase of read length. This
trend may imply that read length would to some degree
affect analysis results of RNA-Seq data, but this hypoth-
esis needs to be further validated in the near future when
more disease-related RNA-Seq data sets are available.
SeqGSEA performance summary and saturation analysis
Recalling the strategies to generate integrated gene
scores, for simplicity, we let “Linear” denote the linear
combination strategy, while “RankSp” and “RankGlb”
denote the rank-based integrative strategy with permuta-
tion-specific normalization and global normalization,
respectively.
As mentioned above, the artificial data set was com-
prised of samples from two tissue types with unmatched
demographics. Thus, as expected, SeqGSEA detected quite
a number of gene sets on the artificial data set (Table 2,
Supplementary Table S1). More importantly, with integra-
tive gene scores proposed in this work, much more gene
sets were detected when comparing with DE-only results
(Supplementary Table S1). Venn diagrams shown in Sup-
plementary Figure S7 further demonstrate that even the
union of the gene sets detected by DE- and DS-only GSEA
cannot cover all detected gene sets using integrated gene
scores with different weights.
A number of significant gene sets were detected by
SeqGSEA at FDR 1% on the three real data sets; presum-
ably because of the small sample size of the BA22 cohort
Table 1 Correlation coefficients of DE and DS scores and experiment statistics of the four data sets.
Data Set Corr. Coef. P-value Sample Size Platform SE/PE Strand Specific Read Length Frag. Size Tissue
Artificial 0.23 0 10 v 9 GAII - - - - -
Cancer 0.05 0 20 v 10 GAII PE No 36 200-300 Prostate
BA46 -0.007 0.17 20 v 20 SOLiD v4 SE Yes 50 200-300 Brain (BA46)
BA22 -0.033 3.4e-9 9 v 9 GAII SE No 76 200-250 Brain (BA22)
Table 2 The number of significant gene sets on the four data sets at FDR 1% with linear combination strategy.
Dataset GS DS 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 DE
Artificial c2 1550 982 1389 1656 1773 1757 1569 1247 696 261 64
c5 647 326 479 681 766 747 675 558 354 158 66
Cancer c2 4 3 4 10 14 16 16 16 14 12 12
c5 11 11 20 14 13 9 6 2 2 1 1
BA46 c2 0 1 1 2 3 3 2 4 3 2 2
c5 0 2 2 2 2 2 2 2 2 1 0
BA22 c2 0 0 0 0 0 0 0 0 0 0 0
c5 0 0 0 0 1 1 1 1 0 0 0
For the full results, see Supplementary Tables S1-S4.
GS: gene set category; DS: DS-only GSEA; DE: DE-only GSEA; 0.1,...,0.9: weights a.
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and apparent batch effect, none or only very few gene sets
were designated significant at FDR 1% (Table 2, Supple-
mentary Tables S2-S4). Comparing with DE- or DS-only
GSEA, essentially, more gene sets were detected to be sig-
nificant using the integrated gene scores, which is similar
as that on the artificial data set. Moreover, some gene sets
could not be detected without the integration of DE and
DS (see Venn diagrams in Supplementary Figures S8-S9);
two extreme cases were observed where significant gene
sets could only be detected by integrated gene scores in c5
on BA46 and BA22 (Supplementary Tables S3 and S4).
When we observed the intersection of detected gene
sets with different weights (Venn diagram cores), only
the artificial data shared gene sets with weights spanning
from 0 to 1 (Supplementary Figures S7-S9). These shared
gene sets were detected by DE-only and DS-only GSEA,
and GSEA with integrated DE and DS scores by any
weights. This is because the artificial transcriptome study
contained samples from different tissue types and with
different demographics, and many genes were subject to
dramatic DE and DS. In contrast, the disease-associated
alteration of the real disease transcriptomes was not
extensive enough, so only one or few GSEA runs among
DE-only, DS-only, or with integrated gene score of a par-
ticular weight could work. This observation in some way
coincided with the correlation between DE and DS scores
on the four data sets described above - comparing with
the real data sets, there were much more genes subject to
significant DE and DS simultaneously in the artificial
data set, causing the correlation coefficients sufficiently
larger than 0.
We also compared the different integration strategies
and found that SeqGSEA with rank-based combination
detected more gene sets that linear combination on the
artificial and the cancer data sets (Supplementary Tables
S1 and S2); however, on the BA46 and the BA22 data,
the results from the two strategies were comparable
(Supplementary Tables S3 and S4). Detailed analysis
showed that most of the detected gene sets with different
combination strategies were overlapped. We also found
that the weight played a particularly critical role on
SeqGSEA’s performance with both linear combination
and rank-based combination strategies, indicating that
the global tuning of DE and DS contribution was more
effective than the data-adapted tuning.
To optimize integration of DE and DS we found it
necessary to explore a range of component weight a to
investigate its effect on the integration efficiency. Clearly,
the number of gene sets detected cannot be the only cri-
terion, because the DE-only analysis still makes biological
sense despite fewer reaching the threshold of statistical
significance. While it would be desirable to test as many
different weights as possible to obtain comprehensive
exploration, we could not enumerate all weights between
0 and 1, as there are infinite possibilities. However, based
on a saturation analysis achieved by gradually adding
more weights to check the unique gene sets detected by
each number of weights, we found that most of SeqGSEA
saturated at 7 or 11 weights regardless of the integration
strategies; in some circumstances there was an increase
when 21 weights were applied, but the increased amount
was either a quite small number or not comparable with
the increase at the beginning (Figure 1 and Supplemen-
tary Figures S10-S14). Therefore, we suggest that in prac-
tice about 11 weights (say 0, 0.1, 0.2,..., and 1) could be
enough, and all detected gene sets with the 11 weights
should be taken to form a comprehensive result. A simi-
lar saturation analysis is also suggested to check whether
the 11 weights are sufficient.
Biological insights
SeqGSEA detected the majority of gene sets on the artifi-
cial data set (Table 2), while the remaining gene sets were
believed to contain genes without sufficient collective
expression/splicing changes. When we examined these
undetected ones, we found that most of them were rele-
vant to housekeeping functions, such as in c2: DNA repli-
cation, cell cycle, and basal transcription factors; in c5:
cellular homeostasis and RNA elongation. This indicates
that the SeqGSEA approach was able to detect overrepre-
sented gene sets with reasonably high specificity.
A detailed analysis on the BA46 results showed that the
detected gene sets are of high biological relevance. For
example, one c5 gene set detected by SeqGSEA in com-
mon with a = 0.2-0.8 shows the regulation of angiogen-
esis is relevant to schizophrenia. It has been reported
that the failure of angiogenesis damages neurogenesis,
particularly in neural structure, and therefore the genes
involved in angiogenesis may also be important for schi-
zophrenia [37]. Interestingly, with a high weight on DS,
two gene sets regarding taste perception were detected.
Evidence also has shown that taste-blindness is highly
associated with schizophrenia [38,39], but more impor-
tantly, our analysis suggested that this association was
largely formulated through the regulation of alternative
splicing. The full results on BA46 with analysis are avail-
able in Supplementary Table S5, and those for the cancer
data are in Supplementary Tables S6-S7. These results
showed that integrating DE and DS for functional analy-
sis yielded biologically meaningful interpretation in dis-
ease transcriptome studies. This analysis also indicated
that specific combination weights could potentially reveal
corresponding predominant regulatory mechanisms in
detected gene sets.
Comparison with other alternative analysis pipelines
The development of SeqGSEA was motivated by the
failure of Cuffdiff analysis to reveal altered genes in the
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two schizophrenia data sets (BA46 and BA22). Noted that
Cuffdiff is still in a positive developing stage, we compared
two versions of Cuffdiff on the three real data sets (see
Supplementary Note #4 for running parameters). In gen-
eral, the newest version 2.0.2 was more stringent than the
older one v1.3.0. Cuffdiff version 2.0.2 didn’t detect any
genes that undergo DE or DS (including differential pro-
moter usage) on the cancer and BA22 data sets. We also
noticed that the new version was very time consuming,
and it failed to finish running the BA46 data within the
running time limit (200 hours) of our HPC server, even
though eight cores were specified to use. Although Cuffdiff
v1.3.0 was less stringent, it only detected one gene
(TMIGD2) as DS on the cancer data, and one gene
(VANGL1) with differential promoter usage on the BA46
data. On the BA22 data set, 6 genes were detected as DS.
With the aid of IPA [40] for functional analysis, no cano-
nical pathways was detected at p-value cutoff 0.05; and top
biological functions given by IPA included functions
related to cancer, carbohydrate metabolism, and endocrine
system development and function, all of which have no
obvious association with schizophrenia. To conclude,
Figure 1 Saturation plots of weights on gene set category c5. Shown are the numbers of unique gene sets detected by different number
of weights indicated in x-axis. (a) is for the artificial data sets; (b) cancer; (c) BA46; (d) BA22. From the fewest to the most number of weights, we
gradually included the following weights in the order of (1 - DE-only, 0 - DS-only, 0.5, 0.1, 0.9, 0.3, 0.7, 0.2, 0.4, 0.6, 0.8, 0.05, 0.15, 0.25, 0.35, 0.45,
0.55, 0.65, 0.75, 0.85, 0.95). Red color indicates “Linear” combination, blue “RankSp”, and black “RankGlb”.
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SeqGSEA was not only more powerful than the pipeline
constructed by Cuffdiff and IPA, but also yielded results of
more biological relevance.
Another possible pipeline could be the traditional DE-
only GSEA, to which the gene expression levels of sam-
ples are fed. The gene expression levels estimated from
RNA-Seq data were generally not well variance stabilized
[41], so we took the degenerated SeqGSEA results when
a = 1 as the DE-only results. The result comparison and
the advantage of SeqGSEA over DE-only have been
described previously. Apparently, either DE-only or DE-
only plus DS-only GSEA is not sufficient to detect all
function-related gene sets. Once again, we suggest the
functional analysis should consider the integration of DE
and DS, which facilitates revealing overrepresented gene
sets in disease transcriptomes more comprehensively and
in a more biologically relevant manner, as it is clearly
that a proportion of genes are subject to both DE and DS
simultaneously.
Conclusions
The method SeqGSEA proposed in this work is particu-
larly useful for efficiently translating HTS transcriptome
read data to biological discoveries, by integrating tran-
scription and splicing, the two respects affecting gene
expression at the RNA level, enhancing the discovery of
overrepresented gene sets with combinatory transcript
abundance changes. It is also beneficial to detect overre-
presented gene sets with only major functional isoforms
switched, where overall transcript abundance levels are
unchanged. As a cutoff-free approach, SeqGSEA does
not require any arbitrary criteria for selecting DE or DS
genes, but generates more informative biological inter-
pretation based on the powerful prototype of the GSEA
method. With a linear combination strategy, SeqGSEA
can potentially throw light on the regulatory preference
of a particular set of genes over transcription regulation
through, for example, transcription factors, or alternative
splicing through splicing factors. SeqGSEA also provides
a framework for integrating other gene-level information
with transcriptome data, such as SNPs, for functional
expression quantitative trait locus (eQTL) analysis.
SeqGSEA is particularly suitable for disease-related
RNA-Seq studies, in which a moderate number of patient
samples with matched controls are available. Most existing
studies are in the order of ten subjects per group [5-8,42],
with a few exceptions of large-scale sequencing studies
with more than one hundred samples (e.g., [43]). The at
least moderate sample size makes it possible for SeqGSEA
to conduct its sample-randomization permutation strategy.
Notably, a sufficient number of human individuals is
vitally important to reach statistical significance and guar-
antee reproducibility because of the considerable biological
variability, although HTS technologies have made the
technical variation small [44]. Moreover, many human dis-
eases display a hierarchical structure, with various sub-
types that have not been completely recognized or
resolved. Pooling samples together with different subtypes
challenges DE/DS gene detection, but GSEA-like
approaches can overcome this by directly considering
biological insight at, for example, the pathway level, accu-
mulating subtype-specific expression alterations in differ-
ent pathogenic genes located in the same pathogenic
pathway.
We have noticed covariates and batch effect involved in
transcriptome studies and other unfavorable biases in
RNA-Seq data may affect SeqGSEA’s results. Sequencing
biases can be adjusted by properly modeling read distri-
butions (e.g., [45]); batch effects and effects from other
covariates including RNA integrity and demographic fac-
tors can be identified and regressed in future develop-
ment of the methodology. Further work will also provide
a basis for reducing ambiguity in the integration strate-
gies, which should enable the implementation of more
sophisticated and facile approaches in future versions.
The results reported in this study were only based on the
Molecular Signatures Database (MSigDB), but in fact any
sets of genes can be fed to SeqGSEA. With more high-
throughput data converting to biology knowledge in the
near future, curated gene sets will be added or improved,
which will in turn yield more biologically significant
results in functional analysis with the aid of computa-
tional tools like SeqGSEA.
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